Co-localization of CD133 and IL-6R may play an important role of cell division for stemness. Some dividing cells expressed co-localization of CD133 and IL-6R. IL-6R was mainly localized at the dividing cells. In the late stages of cultivation, CD133 was mainly localized to the plasma membrane. We demonstrated that CD133 and IL-6R were preferentially concentrated in the complex structure comprising filopodia and lamellipodia. In the present study, we detected CD133 and IL-6R in the human hepatoblastoma cell-line (HuH-6 Clone-5). However, they did not reveal the subcellular localization of CD133 and IL-6R. They also reported the co-localization of CD133 and IL-6R. The prominent distribution of IL-6R was confirmed on the cell surface of CSCs, but not on non-CSCs. reported that the expression of IL-6R in the lung CSCs was markedly up regulated at both the gene and protein levels. However, the role of IL-6R in cancer stem cells (CSCs) is not well defined.IL-6R expression is up regulated in CSCs. The aberrant production and increased secretion of IL-6 in cancer patients is profoundly linked to tumor progression and poor prognosis in many cancer types. There is evidence that IL-6/6R signaling acts as a critical factor for the growth and malignancy of cancer cells. Co-localization of CD133 and IL-6Rwas reported in the lung cancer stem cells (CSCs). Furthermore, an antibody against CD133 decreased cell migration, strongly suggesting that CD133 is involved in tumor cell migration. We also reported the co-localization of CD133 with F-actin. Recently, we reported that CD133 was preferentially concentrated in a complex structure comprising filopodia and the leading edge of lamellipodia. Sarcospheres consisting CD133+ cells exhibited self-renewal, differentiation ability, tumorigenicity, and stemness gene expression. have shown that CD133+ cells from human bone sarcomas display high proliferation rate and that they are capable of forming cluster spheres (sarcospheres). They inoculated the SP fraction cells into NOD/SCID immunodeficient mice, and observed CD133 positive cells in the tumors formed in the mice. separated CSCs by the side population (SP) fraction method from hepatoblastoma cells. However, the biological function of CD133 remains largely unknown. CD133 expression is not restricted to the neuroepithelial and hematopoietic stem/progenitor cells, but extends to several epithelial and non-epithelial cell types. CD133 was first isolated and cloned as an antigen present on the surface of mouse neuroepithelial progenitors, and human hematopoietic stem/progenitor cells. CD133 (also known as Prominin-1 or AC133) has been identified as an important cell surface marker to enrich the stem-like population in various solid tumors, including colon, brain, skin, pancreatic, liver, prostate, and bone, tumors.